Novartis appoints John Tsai as Head of Global Drug Development and CMO

Basel, April 19, 2018 – Novartis announced today the appointment of John Tsai, M.D. as Head of Global Drug Development (GDD) and Chief Medical Officer. Dr. Tsai will join Novartis on May 1, 2018, and will be based in Basel, Switzerland. He will report to Vas Narasimhan, M.D., CEO of Novartis and will become a member of the Executive Committee of Novartis (ECN). He succeeds Dr. Narasimhan who became CEO of Novartis on February 1, 2018. Dr. Rob Kowalski, who led GDD ad interim since February 1, 2018, will resume his responsibilities as Head of Global Regulatory Affairs for GDD.

Dr. Tsai has been Chief Medical Officer and Senior Vice President of Global Medical at Amgen Inc., since May 2017 and oversees all clinical and medical functions across multiple sites worldwide. At Novartis, he will be responsible for advancing the company’s industry-leading pipeline of innovative medicines and biosimilars. Dr. Tsai will also lead the GDD organization’s ongoing transformation embracing the power of advanced data sciences and digital technologies to create a more agile model for drug development.

“I am delighted to welcome John to Novartis,” said Dr. Narasimhan. “As we continue to reimagine drug development, his expertise across multiple therapeutic areas, including cardiovascular, oncology and neuroscience combined with his background in electrical engineering will be a source of great strength for Novartis. John has a great track record in nurturing talent across clinical development, medical affairs and development operations and shares our commitment to build an empowered and inspired organization. I also want to express my sincere gratitude to Rob Kowalski for his excellent ad interim leadership of the GDD organization.”

  • Related Posts

    • Pharma
    • June 23, 2025
    • 118 views
    Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

    LONDON:  Ananda Pharma PLC (AQSE:ANA, OTCQB: ANANF) has manufactured 40 liters of its lead investigational product MRX1 and 40 liters of matched placebo in compliance with pharmaceutical Good Manufacturing Practices…

    • Pharma
    • June 23, 2025
    • 146 views
    Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

    Hyderabad:  In a ray of hope for HIV patients, particularly for the significant burden in the two-Telugu speaking States of Telangana and Andhra Pradesh, several India pharmaceutical companies have secured…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

    Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

    Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

    Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

    Drug licences of 9 pharma dealers suspended in Jammu

    Drug licences of 9 pharma dealers suspended in Jammu

    Sun Pharma Gets Relief on Packaging Norms for Pantoprazole-Levosulpiride FDC

    Sun Pharma Gets Relief on Packaging Norms for Pantoprazole-Levosulpiride FDC